Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
Archives of Pathology & Laboratory Medicine
|
June 4, 2023
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Susana Hernandez, Esther Conde, Aida Molero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations
Alan L Ho, Irene Brana, Robert Haddad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
JAMA Network Open
|
November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Thierry André, Dominique Berton, Giuseppe Curigliano, et al.
Gynecologic Oncology
|
October 23, 2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
Kan Yonemori, Valentina Boni, Kim Gun Min, et al.
Clinical Lung Cancer
|
November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
Bob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
Archives of Pathology & Laboratory Medicine
|
June 4, 2023
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Susana Hernandez, Esther Conde, Aida Molero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations
Alan L Ho, Irene Brana, Robert Haddad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
JAMA Network Open
|
November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Thierry André, Dominique Berton, Giuseppe Curigliano, et al.
Gynecologic Oncology
|
October 23, 2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study
Kan Yonemori, Valentina Boni, Kim Gun Min, et al.
Clinical Lung Cancer
|
November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
Bob T Li, Leena Gandhi, Vignesh Ravichandran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Peter Schmid, Nicholas C Turner, Carlos H Barrios, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Page
of 7